EUVIMEDEUVIMED entdecken
Crossref

Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study

Aditya Tedjaseputra, Sukanya Roy, Kay Htun, Danielle Oh, Zoe McQuilten, Paul Yeh, Ashwini Bennett, Michael Sze Yuan Low, Sanjeev Chunilal, Erica M Wood, Jake Shortt

Pathology · 2024

DOI: 10.1016/j.pathol.2024.01.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology, 2024. Verfasst von Aditya Tedjaseputra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Monash Haematology, Clayton, Vic, Australia. Hauptthemen laut MEDLINE: Staurosporine, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Neoplasm, Residual. Die Arbeit nennt 15 Literaturangaben. Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early induction response assessment with day-21 bone marrow (D21-BM) is commonly performed in patients with FLT3-mutated acute myeloid leukaemia (AML), where detection of residual leukaemia (RL; blasts ≥5%) typically results in the administration of a second induction course. However, whether D21-BM results predict for RL at the end of first induction has not been systematically assessed. This study evaluates the predictive role of D21-BM morphology in detecting RL following first induction. Between August 2018 and March 2022, all patients with FLT3-AML receiving 7+3 plus midostaurin, with D21-BM performed, were identified. Correlation between D21-BM morphology vs D21-BM ancillary flow/molecular results, as well as vs D28-BM end of first induction response, were retrospectively reviewed. Subsequently, D21-BMs were subjected to anonymised morphological re-assessments by independent haematopathologists (total in triplicate per patient). Of nine patients included in this study, three (33%) were designated to have RL at D21-BM, all of whom entered complete remission at D28-BM. Furthermore, only low-level measurable residual disease was detected in all three cases by flow or molecular methods at D21-BM, hence none proceeded to a second induction. Independent re-evaluations of these cases failed to correctly reassign D21-BM responses, yielding a final false positive rate of 33%. In summary, based on morphology alone, D21-BM assessment following 7+3 intensive induction plus midostaurin for FLT3-AML incorrectly designates RL in some patients; thus correlating with associated flow and molecular results is essential before concluding RL following first induction. Where remission status is unclear, repeat D28-BMs should be performed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Staurosporinefms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteNeoplasm, ResidualBone MarrowHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedMutationAntineoplastic Combined Chemotherapy ProtocolsRemission Induction

Stichwörter der Autor:innen

7+3 inductionDay-21 bone marrowFLT3acute myeloid leukaemiafalse positivehaematopathologymidostaurinmorphology

Substanzen

Staurosporinemidostaurinfms-Like Tyrosine Kinase 3FLT3 protein, human

Autor:innen und Institutionen

  • Monash Haematology, Clayton, Vic, Australia.
  • Monash Haematology, Clayton, Vic, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic, Australia.
  • Monash Haematology, Clayton, Vic, Australia; Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Vic, Australia.
  • Monash Haematology, Clayton, Vic, Australia; Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Vic, Australia. Electronic address: jake.shortt@monash.edu.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Tedjaseputra, A., Roy, S., Htun, K., Oh, D., McQuilten, Z., Yeh, P., Bennett, A., Low, M. S. Y., Chunilal, S., Wood, E. M., & Shortt, J. (2024). Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study. Pathology. https://doi.org/10.1016/j.pathol.2024.01.004

Vancouver

Tedjaseputra A, Roy S, Htun K, Oh D, McQuilten Z, Yeh P, et al. Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study. Pathology. 2024. doi:10.1016/j.pathol.2024.01.004

BibTeX
@article{Tedjaseputra2024,
  author = {Tedjaseputra, Aditya and Roy, Sukanya and Htun, Kay and Oh, Danielle and McQuilten, Zoe and Yeh, Paul and Bennett, Ashwini and Low, Michael Sze Yuan and Chunilal, Sanjeev and Wood, Erica M and Shortt, Jake},
  title = {Day-21 bone marrow findings incorrectly designate residual leukaemia in FLT3-mutated acute myeloid leukaemia treated with intensive induction plus midostaurin: a morphology-focused study},
  journal = {Pathology},
  year = {2024},
  doi = {10.1016/j.pathol.2024.01.004}
}
Kostenlos starten →